SCHEMBL6200530

SCHEMBL6200530

O=Cc1cc(O)c2ccccc2c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NQO2 P16083 1/20 0.55
TRPM4 Q8TD43 1/20 0.52
ERN1 O75460 2/20 0.48
KDM4E B2RXH2 2/20 0.47
PTGS2 P35354 1/20 0.47
RAB9A P51151 1/20 0.47
CYP1A2 P05177 2/20 0.45
PTPN1 P18031 1/20 0.45
NQO1 P15559 1/20 0.40
ALDH1A1 P00352 3/20 0.39
PADI4 Q9UM07 1/20 0.39
MEN1 O00255 1/20 0.39
GLA P06280 1/20 0.39
HPGD P15428 1/20 0.39
CYP2C19 P33261 1/20 0.39
KMT2A Q03164 1/20 0.39
HSD17B10 Q99714 1/20 0.39
CYP2A6 P11509 1/20 0.39
AOX1 Q06278 1/20 0.39
ALOX5 P09917 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Formamide SCHEMBL9731174 0.80 NQO2 (0.47) NQO2TRPM4ERN1KDM4ECYP1A2
SCHEMBL11963905 0.80 NQO2 (0.55) NQO2TRPM4ERN1KDM4ECYP1A2
SCHEMBL9731171 0.79 EGFR (0.56) NQO2TRPM4ERN1KDM4EPTGS2
SCHEMBL9098185 0.78 PLAU (0.53) KDM4EPTGS2RAB9ACYP1A2ALDH1A1
SCHEMBL17058718 0.78 ESR1 (0.48) ERN1KDM4EPTGS2RAB9AALDH1A1
SCHEMBL2996328 0.78 ERN1 (0.45) ERN1KDM4ERAB9ACYP1A2PTPN1
SCHEMBL6362144 0.78 CYP1A2 (0.57) ERN1KDM4EPTGS2RAB9ACYP1A2
SCHEMBL31141573 0.78 ERN1 (0.45) ERN1KDM4ERAB9ACYP1A2PTPN1
SCHEMBL29951294 0.78 CYP1A2 (0.57) ERN1KDM4EPTGS2RAB9ACYP1A2
SCHEMBL17988314 0.77 KDM4E (0.56) NQO2TRPM4KDM4ERAB9ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118731194-A Detection method of alkyl diamine 四川科伦药物研究院有限公司 2024-10-01 CN claimed
WO-2025033019-A1 COMPOUND, COMPOSITION, METHOD FOR EXPRESSING SENSITIZING EFFECT, AND PRODUCTION METHOD 三菱瓦斯化学株式会社 2025-02-13 WO disclosed
WO-2024214321-A1 COMPOUND, COMPOSITION, METHOD FOR EXPRESSING SENSITIZING EFFECT, AND METHOD FOR PRODUCING SAME 三菱瓦斯化学株式会社 2024-10-17 WO disclosed
CN-118731194-A Detection method of alkyl diamine 四川科伦药物研究院有限公司 2024-10-01 CN disclosed
US-20240270758-A1 PYRIDINO-OR PYRIMIDO-CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF ZHEJIANG GENFLEET THERAPEUTICS CO., LTD. (CN) 2024-08-15 US disclosed
EP-4332105-A1 PYRIDINO- OR PYRIMIDO-CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF Genfleet Therapeutics (Shanghai) Inc. (CN) 2024-03-06 EP disclosed
CN-117222650-A Pyridine or pyrimido-ring compound, preparation method and medical application thereof 劲方医药科技(上海)有限公司 2023-12-12 CN disclosed
WO-2022228568-A1 PYRIDINO- OR PYRIMIDO-CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF 劲方医药科技(上海)有限公司 2022-11-03 WO disclosed
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed
CN-104470985-B The manufacture method of polymer composition and polymer composition BRIDGESTONE CO.,LTD. (JP) 2016-05-18 CN disclosed
EP-0436902-A1 5-Fluorouracil derivatives OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1991-07-17 EP disclosed
US-4992514-A From mixtures of polyamide and thermotropic liquid crystalline polymer by deforming preform above polyamide glass transition temperature EMS-INVENTA AG (CH) 1991-02-12 US disclosed
US-4983609-A Anticancer agents OTSUKA PHARMACEUTICAL (JP) 1991-01-08 US disclosed
US-4933399-A COATING INSIDE OF VESSEL WITH A CATIONIC DYE, DRYING, COATING WITH AN ANIONIC OR AMPHOTERIC POLYMER OR A HYDROXYL-CONTAINING COMPOUND IN A SOLVENT SHIN-ETSU CHEMICAL CO., LTD. (JP) 1990-06-12 US disclosed
US-4864021-A ANTICARCINOGENIC AGENTS, ANTITUMOR AGENTS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1989-09-05 US disclosed
CN-1035118-A A kind of method that forms polymer-scale that stops SHINETSU CHEMICAL CO (JP) 1989-08-30 CN disclosed
EP-0323441-A2 5-Fluorouracil derivatives OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1989-07-05 EP disclosed
EP-0320227-A2 Method of preventing polymer-scale formation Shin-Etsu Chemical Co., Ltd. (JP) 1989-06-14 EP disclosed
EP-0180897-A2 5-Fluorouracil derivatives OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1986-05-14 EP disclosed
EP-0180188-A2 A composition for increasing the anti-cancer activity of an anti-cancer compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1986-05-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240270758-A1 PYRIDINO-OR PYRIMIDO-CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF KRAS, NRAS, BRAF NQO2 696/4885TRPM4 3811/4885ERN1 3713/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.